


two first formulae on page 6. It is believed that progesterone derivatives of group II should also be examined since they are all progesterone derivatives. The claims falling within the scope of group I are claims 1 to 6, part of claims 7 to 9, 12, 13 part of claim 14 and 34 to 42.

Since the first office action was merely an election of species, a prompt examination on the merits is requested.

Respectfully submitted,


Charles A. Muserlian #19,683
Attorney for Applicants
Tel. 212 302 8989

CAM:mlp
Enclosures

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Charles A. Muserlian
Charles A. Muserlian #19,683

3-23-08

Serial No.: 10/520,637
Goup: 1612

468.001